HC Wainwright Has Lowered Expectations for Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Price

Day One Biopharmaceuticals (NASDAQ:DAWN) had its price objective reduced by equities researchers at HC Wainwright from $40.00 to $36.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price target suggests a potential upside of 281.36% from the stock’s previous close.

Several other brokerages also recently issued reports on DAWN. Bank of America cut their price objective on shares of Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Needham & Company LLC reissued a “buy” rating and set a $33.00 price target on shares of Day One Biopharmaceuticals in a report on Monday, January 13th. TD Cowen raised Day One Biopharmaceuticals to a “strong-buy” rating in a report on Monday, November 4th. Finally, The Goldman Sachs Group lowered their price objective on Day One Biopharmaceuticals from $48.00 to $43.00 and set a “buy” rating on the stock in a research report on Monday, February 10th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $34.86.

Day One Biopharmaceuticals Trading Down 4.4 %

DAWN opened at $9.44 on Wednesday. The stock’s fifty day simple moving average is $12.23 and its 200 day simple moving average is $13.41. Day One Biopharmaceuticals has a 1-year low of $9.43 and a 1-year high of $18.07. The stock has a market cap of $951.99 million, a PE ratio of -9.17 and a beta of -1.46.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.34). The business had revenue of $29.21 million for the quarter, compared to analysts’ expectations of $27.11 million. Equities analysts forecast that Day One Biopharmaceuticals will post -0.72 earnings per share for the current year.

Insider Buying and Selling at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, CEO Jeremy Bender sold 12,048 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total value of $144,094.08. Following the transaction, the chief executive officer now directly owns 128,015 shares of the company’s stock, valued at $1,531,059.40. This trade represents a 8.60 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Charles N. York II sold 4,370 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $52,265.20. Following the completion of the transaction, the chief financial officer now owns 252,638 shares of the company’s stock, valued at $3,021,550.48. The trade was a 1.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 51,064 shares of company stock valued at $651,225 in the last three months. Corporate insiders own 8.40% of the company’s stock.

Institutional Investors Weigh In On Day One Biopharmaceuticals

A number of large investors have recently modified their holdings of the business. GF Fund Management CO. LTD. acquired a new position in shares of Day One Biopharmaceuticals during the 4th quarter worth $27,000. R Squared Ltd bought a new position in Day One Biopharmaceuticals in the fourth quarter valued at about $31,000. Mirae Asset Global Investments Co. Ltd. raised its stake in Day One Biopharmaceuticals by 38.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,611 shares of the company’s stock worth $51,000 after acquiring an additional 1,002 shares in the last quarter. Quest Partners LLC lifted its holdings in shares of Day One Biopharmaceuticals by 9,238.6% in the third quarter. Quest Partners LLC now owns 7,751 shares of the company’s stock worth $108,000 after acquiring an additional 7,668 shares during the last quarter. Finally, Tower Research Capital LLC TRC boosted its stake in shares of Day One Biopharmaceuticals by 911.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 10,657 shares of the company’s stock valued at $135,000 after purchasing an additional 9,603 shares in the last quarter. Institutional investors and hedge funds own 87.95% of the company’s stock.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.